Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cocrystal Pharma, Inc. (NASDAQ: COCP).

Full DD Report for COCP

You must become a subscriber to view this report.


Recent News from (NASDAQ: COCP)

Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update
ATLANTA, GA and BOTHELL, WA, May 11, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication ...
Source: GlobeNewswire
Date: May, 11 2018 08:00
Cocrystal Pharma to Present at the Fred Hutch and Merck Infectious Disease Summit
- Presentation on Thursday, May 10 at 11:15 AM PDT - ATLANTA, GA and BOTHELL, WA, May 10, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing ...
Source: GlobeNewswire
Date: May, 10 2018 08:30
COCRYSTAL PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING
TUCKER, GA and BOTHELL, WA, May 01, 2018 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) , (“Cocrystal” or the “Company”) a clinical stage biotechnology company focused on developing innovative antiviral therapeutics, today announced the pricing o...
Source: GlobeNewswire
Date: May, 01 2018 08:30
Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus
– Company on track to commence patient enrollment and dosing in Q2 2018 – – Topline data from Phase 2a study expected in Q4 2018 – ATLANTA, GA and BOTHELL, WA, April 03, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal...
Source: GlobeNewswire
Date: April, 03 2018 08:00
Cocrystal Pharma Reports 2017 Financial Results and Provides Corporate Overview and Business Outlook
–Company successfully completes uplisting to the NASDAQ Capital Market – –Company positioned to achieve clinical and regulatory milestones over the course of 2018– ATLANTA, GA and BOTHELL, WA, March 22, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. &#x...
Source: GlobeNewswire
Date: March, 22 2018 07:05
Cocrystal Pharma Announces Uplist to The Nasdaq Capital Market
ATLANTA, GA and BOTHELL, WA, March 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replicatio...
Source: GlobeNewswire
Date: March, 12 2018 08:30
Cocrystal Pharma Provides Update on Reverse Stock Split
- Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB: COCP), (“Cocrystal” or the “C...
Source: GlobeNewswire
Date: January, 23 2018 16:30
Cocrystal Pharma Announces 1-for-30 Reverse Stock Split
– Reverse stock split positions Company to uplist to the NASDAQ Capital Market in Q1 2018 – – Company expects to commence Phase 2a study in Q1 2018 for lead program, CC-31244, for the treatment of hepatitis C infection – – Company positioned to a...
Source: GlobeNewswire
Date: January, 23 2018 09:15
Cocrystal Pharma Announces Filing 2017 Third Quarter Financial Statements and Provides Company Update
ATLANTA, GA and BOTHELL, WA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its financial statements for the quarter ending September 30, 2017 and provided...
Source: GlobeNewswire
Date: November, 08 2017 17:30
Cocrystal Pharma to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York
ATLANTA, GA and BOTHELL, WA--(Marketwired - Sep 22, 2017) - Cocrystal Pharma, Inc. ( OTCQB : COCP ) today announced that Dr. Gary Wilcox and James Martin will be presenting a company overview at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 8:35am in...
Source: Marketwired
Date: September, 22 2017 08:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-181.96011.892.031.8362,046
2018-05-171.96011.892.031.8362,046

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-152,9438,00036.7875Short
2018-08-141,3008,04716.1551Cover
2018-08-135,71058,6329.7387Cover
2018-08-101571,00115.6843Cover
2018-08-091,8432,13386.4041Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on COCP.


About Cocrystal Pharma, Inc. (NASDAQ: COCP)

Logo for Cocrystal Pharma, Inc. (NASDAQ: COCP)

Cocrystal is a clinical stage biotechnology company which develops novel medicines for use in the treatment of human viral diseases. Cocrystal has developed proprietary structure based drug design technology and antiviral nucleoside chemistry to create first in class and best in class antiviral drug candidates. Our focus is to pursue the development and commercialization of broad spectrum antiviral drug candidates that will transform the treatment and prophylaxis of hepatitis C, Influenza, and Norovirus. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas.

 

Contact Information

 

 

Current Management

  • Gary Wilcox / Interim CEO
  • Sam Lee / President
  • James J. Martin / CFO
  • Raymond Schinazi / Chairman
  • Gary Wilcox / Chairman
  • David Block /
  • Phillip Frost /
  • Jane H. Hsiao /
  • Steve Rubin /

Current Share Structure

  • Market Cap: $119,325,511 - 03/15/2018
  • Authorized: 800,000,000 - 03/06/2018
  • Issue and Outstanding: 24,402,444 - 03/06/2018

 


Recent Filings from (NASDAQ: COCP)

Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 11 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 03 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018

 

 


Daily Technical Chart for (NASDAQ: COCP)

Daily Technical Chart for (NASDAQ: COCP)


Stay tuned for daily updates and more on (NASDAQ: COCP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: COCP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in COCP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of COCP and does not buy, sell, or trade any shares of COCP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/